Colorectal Cancer (CRC)NCT07082335
Clinical Characteristics and Prognosis of Simultaneous Versus Delayed Resection for Synchronous Colorectal Liver Metastasis: A Nationwide Multicenter Study Utilizing Propensity Score Matching Analysis
An observational study of Colorectal Cancer (CRC), run by Shanghai 10th People's Hospital at 1 site in China.
Trial summary
Colorectal cancer (CRC) often metastasizes to the liver, with synchronous metastases observed in 20% of cases. Surgical resection is the primary treatment, but the impact of simultaneous and staged resections on clinical outcomes remains unclear. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Colorectal Cancer (CRC)
- How many people
- 679 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2019to 1 Jan 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This nationwide multicenter retrospective cohort study enrolled colorectal cancer patients with simultaneous liver metastases treated at 18 tertiary hospitals in China between January 2019 and December 2021.
Who may be able to join
- 1) a histologically confirmed diagnosis of colorectal cancer with liver metastases; and 2) age ≥ 18 years
Who cannot join
- 1) extrahepatic metastases; and 2) ineligibility for curative surgical resection based on preoperative assessment.
Trial locations and contacts
1 site in 1 country.
China1 site
Shanghai Tenth People Hospital, Yanchang Road, Jingan District, Shanghai,
Shanghai, Jingan, 200040
About this study
Colorectal cancer (CRC) often metastasizes to the liver, with synchronous metastases observed in 20% of cases. Surgical resection is the primary treatment, but the impact of simultaneous and staged resections on clinical outcomes remains unclear. This study employs propensity score matching (PSM) in a nationwide survey to compare clinical characteristics, complications, and survival, providing valuable insights for optimizing the management of colorectal liver metastases.
- Conditions
- Colorectal Cancer (CRC)
- Medical subject headings
- Colorectal Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
overall survival
Measured: 2 years
postoperative complications
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2025
- Study start1 Jan 2019
- Primary completion1 Jan 2021
- Study completion1 Jan 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal Cancer (CRC)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 679 participants (actual)
Sponsor and investigators
- Lead sponsor
- Shanghai 10th People's Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- RenJi Hospital
- Responsible party
- Principal investigator, Zhang Feng-Min, Shanghai 10th People's Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07082335
- Sponsor's protocol ID
- 25K10
- Status last verified
- Jul 2025
- First submitted
- 16 Jul 2025
- Last updated
- 22 Jan 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 22 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Characteristics and Prognosis of Simultaneous Versus Delayed Resection for Synchronous Colorectal Liver Metastasis: A Nationwide Multicenter Study Utilizing Propensity Score Matching Analysis
- ClinicalTrials.gov ID
- NCT07082335
- Acronym / sponsor ID
- 25K10
- Conditions
- Colorectal Cancer (CRC)
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 679 participants (actual)
- Lead sponsor
- Shanghai 10th People's HospitalUniversity, hospital or other
- Collaborators
- RenJi Hospital
- Study start
- 1 Jan 2019 (actual)
- Primary completion
- 1 Jan 2021 (actual)
- Study completion
- 1 Jan 2024 (actual)
- First posted
- 24 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Colorectal cancer (CRC) often metastasizes to the liver, with synchronous metastases observed in 20% of cases. Surgical resection is the primary treatment, but the impact of simultaneous and staged resections on clinical outcomes remains unclear. This study employs propensity score matching (PSM) in a nationwide survey to compare clinical characteristics, complications, and survival, providing valuable insights for optimizing the management of colorectal liver metastases.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This nationwide multicenter retrospective cohort study enrolled colorectal cancer patients with simultaneous liver metastases treated at 18 tertiary hospitals in China between January 2019 and December 2021.
Key inclusion criteria (1 listed)
- 1) a histologically confirmed diagnosis of colorectal cancer with liver metastases; and 2) age ≥ 18 years
Key exclusion criteria (1 listed)
- 1) extrahepatic metastases; and 2) ineligibility for curative surgical resection based on preoperative assessment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
overall survival
Time frame: 2 years
postoperative complications
Time frame: 1 month
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Colorectal Cancer (CRC)
RecruitingPhase 3
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Metastatic Colorectal Cancer (CRC)
Not yet recruiting
Improving Colorectal Cancer Screening Uptake Through Education and Stool-Based Testing Outreach
Colorectal Cancer (CRC) Screening, CRC Screening
RecruitingPhase 1/2
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Advanced Solid Tumors, Metastatic Solid Tumors
RecruitingPhase 1
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Solid Tumor, Adult, Metastatic Solid Tumor
RecruitingPhase 1
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
KRAS G12C Mutation, KRAS G12S Mutation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colorectal Cancer (CRC), run by Shanghai 10th People's Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
overall survival (time frame: 2 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jan 2026; AzTrials last refreshed its copy on 7 Nov 2026.